Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-C...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Livre |
| Publié: |
MDPI AG,
2022-03-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_9c0ad6bc95dc4e5ca1ff7a75728e0b9a | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Lorenza Romani |e author |
| 700 | 1 | 0 | |a Francesca Ippolita Calò Carducci |e author |
| 700 | 1 | 0 | |a Sara Chiurchiù |e author |
| 700 | 1 | 0 | |a Laura Cursi |e author |
| 700 | 1 | 0 | |a Maia De Luca |e author |
| 700 | 1 | 0 | |a Martina Di Giuseppe |e author |
| 700 | 1 | 0 | |a Andrzej Krzysztofiak |e author |
| 700 | 1 | 0 | |a Laura Lancella |e author |
| 700 | 1 | 0 | |a Paolo Palma |e author |
| 700 | 1 | 0 | |a Leonardo Vallesi |e author |
| 700 | 1 | 0 | |a Tiziana Corsetti |e author |
| 700 | 1 | 0 | |a Andrea Campana |e author |
| 700 | 1 | 0 | |a Emanuele Nicastri |e author |
| 700 | 1 | 0 | |a Paolo Rossi |e author |
| 700 | 1 | 0 | |a Stefania Bernardi |e author |
| 245 | 0 | 0 | |a Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| 260 | |b MDPI AG, |c 2022-03-01T00:00:00Z. | ||
| 500 | |a 10.3390/children9030369 | ||
| 500 | |a 2227-9067 | ||
| 520 | |a Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old. | ||
| 546 | |a EN | ||
| 690 | |a COVID-19 | ||
| 690 | |a monoclonal antibody | ||
| 690 | |a children | ||
| 690 | |a Pediatrics | ||
| 690 | |a RJ1-570 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Children, Vol 9, Iss 3, p 369 (2022) | |
| 787 | 0 | |n https://www.mdpi.com/2227-9067/9/3/369 | |
| 787 | 0 | |n https://doaj.org/toc/2227-9067 | |
| 856 | 4 | 1 | |u https://doaj.org/article/9c0ad6bc95dc4e5ca1ff7a75728e0b9a |z Connect to this object online. |